A ways back I remarked on the need to be patient with Lexaria because their struggle was essentially that they had either:
(a) a "proven" formulation for [what was at the time] an illegitimate market - i.e., cannabis, or
(b) an "unproven" formulation for the legitimate markets - i.e., nicotine, pharma, etc..
Now:
(a) the illegitimate market has become legitimate (not to mention - with massive potential), and
(b) the "unproven" formulation has been proven (not to mention - again, with massive potential).
The "nicotine subsidiary" represents the first major move forward with either (a) or (b). (With multiple huge opportunities that could be taken advantage of in each!!)
All that said, I'm expecting things to really start moving here - all the pieces are finally in place. "In Bunka We Trust."